In California, Amyris and India’s Ipca Laboratories have signed a Letter of Intent (LOI) to establish an agreement for Amyris to supply a key starting material for an active pharmaceutical ingredient to Ipca. This initial ingredient is expected to enable Ipca to more reliably and cost effectively compete with other manufacturers in the production of one its key pharmaceutical ingredients. It is anticipated that as further developments occur toward the signing of a definitive agreement that both companies will work together on other possible collaborations for additional pharmaceutical ingredients.
Earlier this year, Amyris launched an initiative under its µPharm™ (microPharm) discovery platform to add leading pharmaceutical companies to its array of collaboration and other partners. This strategic initiative was born of Amyris’s historical expertise in creating a reliable supply of artemisinin for the treatment of malaria. Today’s announcement marks an important step forward by Amyris in both building out and diversifying its customer base in the pursuit of large and growing global markets, such as the pharmaceuticals sector.
“We are pleased to sign this letter of intent with Ipca, which illustrates our ability to solve supply and time-to-market problems for companies in a variety of sectors,” said John Melo, President & CEO of Amyris. “The biopharma sector poses an attractive growth opportunity for Amyris to pursue, and we are in ongoing discussions with several other potential partners in this space.”